Dendritic cell-based cancer therapy.

Article Details

Citation
Copy to clipboard

Conrad C, Nestle FO

Dendritic cell-based cancer therapy.

Curr Opin Mol Ther. 2003 Aug;5(4):405-12.

PubMed ID
14513684 [ View in PubMed
]
Abstract

Dendritic cell (DC)-based cancer immunotherapy has been shown to be safe and feasible. In clinical pilot studies, DCs primed with tumor antigens have successfully been used to induce tumor-specific immunity and obtain some clinical responses in cancer patients. Even though many advances have been achieved over the past years, we are still far from a unifying therapy concept. This review will discuss the current research driving the rapidly growing field of DC-based cancer immunotherapy and highlight some recent progress related to critical issues such as DC preparation, choice and loading of antigen, and the route of administration.

DrugBank Data that Cites this Article

Drugs